This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Rebetol
  • /
  • A Study to Evaluate the Efficacy and Safety of ABT...
Clinical trial

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study (MAGELLAN-3)

Read time: 3 mins
Last updated:21st Nov 2016
Identifier: NCT02939989

The purpose of this study is to evaluate the efficacy and safety of co-administration of ABT-493/ABT-530 plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT) 1 - 6-infected participants (including non-cirrhotic, or cirrhotic participants) who have experienced virologic failure in an AbbVie parent clinical study.


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 50 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies (MAGELLAN-3)
Actual Study Start Date: November 21, 2016
Estimated Primary Completion Date: June 28, 2020
Estimated Study Completion Date: September 28, 2020

Arms:
- Experimental:
ABT-493/ABT-530 + SOF + RBV for 16 weeks
- Experimental: ABT-493/ABT-530 + SOF + RBV for 12 weeks

Category Value
Date last updated at source 2019-06-14
Study type(s) Interventional
Expected enrolment 50
Study start date 2016-11-21
Estimated primary completion date 2020-06-28

View full details